- Home
- REAX vs ANIP Comparison
REAX vs ANIP Comparison
Compare REAX & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAX
- ANIP
- Stock Information
- Founded
- REAX 2018
- ANIP 2001
- Country
- REAX United States
- ANIP United States
- Employees
- REAX N/A
- ANIP N/A
- Industry
- REAX
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- REAX
- ANIP Health Care
- Exchange
- REAX Nasdaq
- ANIP Nasdaq
- Market Cap
- REAX 1.1B
- ANIP 1.2B
- IPO Year
- REAX N/A
- ANIP N/A
- Fundamental
- Price
- REAX $4.89
- ANIP $55.35
- Analyst Decision
- REAX Strong Buy
- ANIP Buy
- Analyst Count
- REAX 2
- ANIP 7
- Target Price
- REAX $5.25
- ANIP $77.33
- AVG Volume (30 Days)
- REAX 773.3K
- ANIP 253.7K
- Earning Date
- REAX 11-07-2024
- ANIP 11-08-2024
- Dividend Yield
- REAX N/A
- ANIP N/A
- EPS Growth
- REAX N/A
- ANIP N/A
- EPS
- REAX N/A
- ANIP N/A
- Revenue
- REAX $1,095,350,000.00
- ANIP $555,456,000.00
- Revenue This Year
- REAX $79.06
- ANIP $25.49
- Revenue Next Year
- REAX $30.06
- ANIP $19.92
- P/E Ratio
- REAX N/A
- ANIP N/A
- Revenue Growth
- REAX 81.37
- ANIP 23.60
- 52 Week Low
- REAX $1.46
- ANIP $52.00
- 52 Week High
- REAX $6.75
- ANIP $70.81
- Technical
- Relative Strength Index (RSI)
- REAX 41.36
- ANIP 42.29
- Support Level
- REAX $4.83
- ANIP $55.29
- Resistance Level
- REAX $5.35
- ANIP $57.33
- Average True Range (ATR)
- REAX 0.23
- ANIP 1.88
- MACD
- REAX -0.03
- ANIP -0.16
- Stochastic Oscillator
- REAX 13.59
- ANIP 5.34
About REAX The Real Brokerage Inc.
The Real Brokerage Inc is a technology-powered real estate brokerage firm. It has developed, integrated, and adopted various mobile and desktop-focused technologies to create a comprehensive offering to its agents and to assist Real with its brokerage operations. The group delivers a cloud-based platform to improve efficiencies and empower real estate agents to provide a seamless end-to-end experience for homebuyers and sellers. The company generates its maximum revenue from the United States.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.